Why 4 Medical Societies Issued a Joint Advisory on Nutrition and GLP-1 Therapy for Obesity
Coauthor of a recent joint advisory, Jonathan Bonnet, MD, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.
Remote Cognitive Screening Platform Expands Access to Early Detection
Linus Health is expanding its AI-powered remote cognitive assessment platform, Anywhere, to expand access to early detection of cognitive impairment.
Solriamfetol Treatment Yields Cognitive Gains in Obstructive Sleep Apnea: Daily Dose
Your daily dose of the clinical news you may have missed.
Trontinemab Phase 3 Alzheimer Trials to Launch Following Promising Amyloid Clearance Data
Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.
Low-Value Cancer Screenings Persist Despite Guidelines: Daily Dose
The Obesity–Cardiometabolic Link: Root Causes, Screening, and Primary Care's Role
Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.
In Screening for Dementia, Time Can Tell A Lot: A Conversation with Researcher David Libon, PhD
In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.
FDA Extends Review Period for Elinzanetant NDA for Menopausal Vasomotor Symptoms
Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.
Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds
Nirsevimab lowered the risk of RSV-related illness by over 87% and hospitalizations by 98% in a new study.
EMA Advisory Group Issues Positive Opinion on Lilly's Donanemab for Treatment of Early Alzheimer Disease
The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.
7 Common Causes of Dementia: A Topline Review
The brain changes that lead to cognitive and behavioral changes referred to as dementia have multiple potential etiologies; not all dementia is Alzheimer disease.
Late-Life Mood Disorders May Represent Prodromal States of Dementia: Daily Dose
AI-Generated Dermatologic Images Show Poor Diagnostic Accuracy, Underrepresent Skin of Color
In response to the prompt, "Generate a photo of a person with [skin condition]," 3 of 4 generative AI models significantly underrepresented diverse skin tones.
Make It Routine: Screening for Cognitive Decline in Primary Care
Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.
Influenza Vaccination Reduces Disease Burden in Both Vaccinated and Unvaccinated, Modeling Study Finds
Vaccination lowered influenza cases by about 33% to 42% in seasonal flu setups with 40% vaccine effectiveness, researchers reported.
FDA Grants Fast Track Designation for Sprout's Flibanserin to Treat HSDD in Postmenopausal Women
Low sexual desire affects up to 40% of women across the lifespan but currently there is no treatment option for those beyond their reproductive years.
FDA Advisory Panel Calls for Revised Class Labeling for Menopausal Hormone Replacement Therapy
Experts reviewed data from the 2002 Women's Health Initiative study that prompted class warnings for estrogen-containing therapies and called for changes, education.
GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes
Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.
Real-World GLP-1 RA Discontinuation Tied to Modest Weight Loss: Daily Dose
FDA Approves Delgocitinib, First Treatment for Adults with Moderate to Severe Chronic Hand Eczema
The nonsteroidal topical pan-JAK inhibitor provides a potent treatment option for adults with CHE who have not responded to corticosteroids or cannot tolerate them.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Why 4 Medical Societies Issued a Joint Advisory on Nutrition and GLP-1 Therapy for Obesity")
